Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Colorado, Denver
With
US Department of Veterans Affairs
Pfizer
Age
30–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Sedentary adults not participating in a regular exercise program (≤ one bout of scheduled exercise per week)
Subjects must have Type 2 Diabetes
Subjects must be otherwise healthy
Ages of 30-60 years
BMI of 25-39 and stable weight for 3 months prior to the start of the study
Diabetes controlled by diet +/- insulin secretagogues (sulfonylureas or glinides), metformin, or glucose absorption blockers (acarbose).
Total glycosylated hemoglobin levels (HbA1C) ≤9% (fair control) on current therapy.
You may not be if
Any comorbid condition which could limit exercise performance including Chronic Obstructive Pulmonary Disease (COPD) or asthma
Concurrent enrollment in an interventional study.
Any tobacco use either current or within the last year
Clinically evident distal symmetrical neuropathy, determined by evaluation of symptoms (numbness, paresthesia) and signs (elicited by vibration, pinprick, light touch, ankle jerks), will be excluded.
Autonomic dysfunction (\>20 mm fall in upright BP without a change in heart rate) will be excluded.
Evidence of ischemic heart disease by history or abnormal resting or exercise electrocardiogram (EKG) (\> 1 mm ST segment depression) on screening exercise test.
Angina or any other cardiovascular, pulmonary or musculoskeletal symptoms
Presence of systolic blood pressure \>190 at rest or \>250 with exercise or diastolic pressure \>95 at rest or \>105 with exercise
Proteinuria (urine protein \>200 mg/dl) or a creatinine \> 2 mg/dl, suggestive of severe renal disease
